Crinetics Announces Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome


Crinetics announces positive initial findings from its ongoing open-label Phase 2 carcinoid syndrome study of paltusotine, an oral, once-daily investigational compound being developed for the treatment of acromegaly and carcinoid syndrome.

Crinetics Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 42,450 shares of its common stock to five new non-executive employees

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update


Crinetics Pharmaceuticals today reported financial results for the fourth quarter and full year ended December 31, 2023.

Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement


Crinetics announces that it has agreed to sell 8,333,334 shares of its common stock at a price of $42.00 per share to a select group of institutional and accredited healthcare specialist investors.

Crinetics Pharmaceuticals To Report Fourth Quarter And Full Year 2023 Financial Results On February 28, 2024


Crinetics will host a conference call and webcast on February 28th at 4:30 p.m. ET to discuss fourth quarter and full year 2023 financial results and provide a business update.